BMJ  2005;330 (28 May), doi:10.1136/bmj.330.7502.0-e

No need to pay if a drug doesn't work?

Møldrup argues (p 1262) that not paying for a drug unless it works would not only benefit patients and healthcare funders, but it could also benefit drug manufacturers. He discusses the main tensions in the current marketing situation, explains the "no cure, no pay" strategy, and gives examples of some ways in which it has been implemented in the past decade. The strategy would also encourage therapeutic evaluations and reduce use of ineffective treatments, says the author, but he also acknowledges the need for more evidence and wider debate of the proposal.

Credit: MEPL

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

No cure, no pay

Claus Møldrup
BMJ 2005 330: 1262-1264. [Extract] [Full Text] [PDF]

Rapid Responses:

Read all Rapid Responses

And what if......?

Alan Challoner
bmj.com, 27 May 2005 [Full text]

Simply a gimmick

John Stone
bmj.com, 28 May 2005 [Full text]